DBV Technologies price to book ratio DBVT
Market value divided by the book value of the company's net assets, since 2021.
- Today, Nov 2, 2026
- 3.8×
- 6-year median
- 0.3×
- Against its 6-year history
- 76th
- percentile: 0 is its lowest day, 100 its highest
- 6-year range
- 0.1× to 111×
- Peer median
- 4.9×
DBV Technologies' price to book ratio is 3.8× as of Nov 2, 2026.
That is above its 6-year median of 0.3×, higher than on 76% of days in the last 6 years.
Over that time it ranged from 0.1× in Jun 2024 to 111× in Jul 2025.
The median for 4 biotech stocks of a similar size is 4.9×.
Price to book ratio over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 3.8× | 3.3× | 15.7× |
| 2025 | 12.3× | 0.2× | 111× |
| 2024 | 0.2× | 0.1× | 0.3× |
| 2023 | 0.1× | 0.1× | 0.2× |
| 2022 | 0.1× | 0.1× | 0.4× |
| 2021 | 0.2× | 0.2× | 0.4× |
Against its peers
Companies in Biotechnology nearest DBV Technologies' size, closest first, today.
| Company | Price to book ratio |
|---|---|
| DBVTDBV Technologies | 3.8× |
| MGTXMeiraGTx | 4.2× |
| PLXProtalix BioTherapeutics | 2.9× |
| VCELVericel | 5.6× |
| ADMAAdma Biologics | 6.1× |
| Peer median | 4.9× |
What the price to book ratio tells you
Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.
Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.
More on DBV Technologies
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.